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no PCR products in either reaction, indicating that
the target sequences of the cagA primers were
mutated or deleted. The 28 isolates with ambigu-
ous PCR results were excluded from the evalua-
tion in Table 1. However, if they were included
and regarded as cag PAI+, in accordance with the
interpretations made above, the kappa coefﬁcient
was estimated as 0.80 (95% CI 0.64–0.95), com-
pared with 0.57 (95% CI 0.40–0.75) if they were
regarded as cag PAI–. The former value is essen-
tially identical to that in Table 1, thereby sup-
porting the original interpretations. The
occurrence of such PCR ambiguities could be
reduced by examining single-colony isolates, but
this increases the risk of overlooking strain
variants unless numerous colonies are included.
In conclusion, agreement between the results of
tests to determine the serological CagA status and
the cag PAI PCR results of H. pylori infections is
satisfactory, considering the biological prerequi-
sites. Genotypic approaches are required when
the characteristics of individual bacterial clones
are being studied. However, in the clinical and
epidemiological settings, current and past infec-
tions of the whole gastric mucosa are typically of
interest. Genotypic methods are then limited by
the availability of biological specimens from
sometimes asymptomatic individuals, and by
the need to assess strain variants dispersed
throughout the stomach. Despite previous advice
against serology [4], the present data support the
application of well-evaluated serological assays in
clinical and epidemiological studies.
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ABSTRACT
This study assessed immunity to poliomyelitis in
a representative sample of 1064 persons living in
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northern Greece. Antibody prevalences in the
individuals tested were 91.1% (95% conﬁdence
interval (CI): 89.4–92.8), 92.1% (95% CI: 90.5–93.7)
and 83.1% (95% CI: 80.8–85.4) for poliovirus
types 1, 2 and 3, respectively. For poliovirus type
3, a gap in immunity was found in individuals
aged 10–29 years. Re-vaccination of adolescents
living in northern Greece is suggested to ensure
herd immunity and to minimise the risk of
importation of wild poliovirus from endemic
countries.
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In the 12 years since the World Health Organiza-
tion (WHO) launched its initiative to eradicate
poliomyelitis by the year 2000, the annual number
of cases of poliomyelitis reported to WHO has
dropped from >35 000 to 2880 [1]. The eradica-
tion of poliomyelitis has been complicated by
events such as the importation of wild poliovi-
ruses into polio-free countries and the circulation
of neurovirulent vaccine-derived polioviruses
[2,3]. As a consequence, the WHO target for
poliomyelitis eradication has been reset to 2005.
Greece has been free of indigenous cases of
poliomyelitis since 1982 [4], but an outbreak of
paralytic disease caused by a wild type 1 polio-
virus occurred in the neighbouring country of
Albania in 1996 [5]. During the same period, ﬁve
cases of poliomyelitis occurred in Greece in non-
vaccinated Gypsy children. The close homology
of these Greek isolates with the Albanian geno-
type suggested direct virus importation [6].
Oral polio vaccine was introduced into Greece
in 1964, and was offered to 2 million persons aged
£ 18 years [7]. After 1964, a standard vaccination
schedule was initiated, and this remains in force
today. Four doses are scheduled at the age of 2, 4,
6 and 18 months, with a booster dose at 4–6 years.
The estimated vaccination coverage with three or
four documented doses, independent of age at
immunisation, has been > 95% since 1990, but
there have been delays in the receipt of three
doses by the age of 1 year [8]. Serosurveillance is
of value in countries where there are pockets of
non-vaccinated individuals [9]. The main objec-
tive of the present study was to gain an insight
into possible gaps in immunity in the northern
Greek population.
The study was carried out in 2001–2002 and
involved 1064 apparently healthy individuals (550
males and 514 females), aged from 3 months to
‡ 70 years, living in 17 prefectures in northern
Greece (total population 2.8 million). The prefec-
tures were sampled in proportion to the number
of individuals in each age group, based on the
2001 census [10]. An age-stratiﬁed sample was
selected from each prefecture by single random
sampling.
Antibodies against poliovirus types 1, 2 and 3
were determined with a microneutralisation assay
with prototype Sabin strains, according to the
WHO guidelines [11]. Sera were heat-inactivated,
diluted two-fold from 1:8 to 1:1024, and then
incubated in duplicate for 3 h at 36C with
100 · 50% tissue culture infective dose (TCID50)
of poliovirus antigen. A cell suspension contain-
ing 2 · 104 L20B cells ⁄ 0.1 mL was added. Cell
controls and an in-house reference serum sample
of known neutralising activity were included in
each batch. After incubation for 5 days, the
highest dilution of serum that protected 50% of
the cultures was recorded. A serum sample was
considered positive if antibodies were present at a
dilution ‡ 1:8. Results were expressed as log2
reciprocal titres (log2 titre 1 : 8 = 3). The chi-
square test was used for group comparisons of
the seroprevalence, and Student’s t-test was used
to analyse differences between geometric mean
titres (GMTs).
Tables 1 and 2 show that the population in
northern Greece is generally well-protected
against poliovirus types 1 and 2, but less so
against type 3, the seroprevalences being 91.1%,
92.1% and 83.1%, respectively, according to
WHO criteria. While the seroprevalence of types
1 and 2 was found to be close to or > 90% in
almost all age groups, unsatisfactory levels
of immunity were observed for type 3 in the
group aged 10–29 years (seroprevalence range
75–76.2%, p 0.013–0.003).
Although individuals with a neutralising anti-
body titre of ‡ 1:8 are regarded as immune, it is
unclear whether all individuals with undetectable
antibodies are susceptible to infection, partic-
ularly the elderly, who may be protected by
memory immunity. Immunity to poliovirus is
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largely dependent on humoral antibodies, but the
production of intestinal IgA may also play a
signiﬁcant role [12].
As systematic polio vaccination was introduced
in Greece in 1964, it can be assumed that the
antibodies detected were mainly attributable to
natural infection in individuals born before 1946,
whereas those in individuals born after 1964, and
in most individuals born between 1946 and 1964,
were mainly vaccine-induced.
The seroprevalence of poliovirus types 1 and 2
was higher than that of type 3, and this ﬁnding
might be attributable to the lower potency of
poliovirus type 3 antigens. For all types, the
highest prevalence and GMTs were found in
children aged 1–9 years, indicating a good
response to primary vaccination and the booster
dose. In groups aged 10–19 years, high levels of
immunity were found for poliovirus types 1 and
2, while lower but still high levels were found in
groups aged 20–49 years. These results are con-
sistent with those reported in other studies, and
might be explained in some individuals by a
booster effect caused by continued exposure to
the wild virus [13,14]. The seroprevalence was
also high, with stable antibody titres, in individ-
uals aged ‡ 50 years, which probably represents
predominantly natural immunity. Similar ﬁnd-
ings have been reported in some other countries
[13,15–18].
The lowest seroprevalence was observed for
type 3 virus in groups aged 10–29 years. This
indicated an unsatisfactory level of immunity in
adolescents and young adults. Signiﬁcantly low
GMTs were also found in these age groups. These
results are consistent with those of some previous
studies performed in other European countries
[16,19]. The delays in receipt of oral polio vaccine
doses, or the fact that a booster dose was not
given since infancy, may have contributed to the
decline in titres of neutralising antibodies.
In the present study, females aged 20–39 years
had better protection than males in the same
group (data not shown), possibly because of
closer contact with small children vaccinated
recently. The possible role of secondary spread
of vaccine virus is supported by the ﬁndings of
other studies [20].
In conclusion, the serological status of the
population of northern Greece against poliovirus
is at a high level for types 1 and 2. The low
percentages of protective antibodies to poliovirus
type 3 in adolescents and young adults suggest
the need for a booster dose of vaccine to ensure
personal and herd immunity and to minimise the
risk of importation of wild poliovirus from
endemic countries.
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Table 1. Age-speciﬁc prevalence of antibodies (95% con-
ﬁdence interval (CI)) against poliovirus types 1, 2 and 3 in
1064 individuals living in northern Greece, 2001–2002
Age group
No.
tested
Poliovirus type
1 protective
antibodies
Poliovirus type
2 protective
antibodies
Poliovirus type
3 protective
antibodies
% 95% CI % 95% CI % 95% CI
3–11 months 66 84.8 76.1–93.5 89.4 82.0–96.8 78.8 69.0–88.6
1–4 years 91 96.7 93.0–100 96.7 93.0–100 87.9 81.2–94.6
5–9 years 107 97.2 94.1–100 98.1 95.5–100 89.7 83.9–95.5
10–14 years 104 96.2 92.5–99.9 96.2 92.5–99.9 75.0a 66.8–83.2
15–19 years 80 95.0 90.2–99.8 96.2 91.9–100 76.2a 66.9–85.5
20–29 years 117 89.7a 84.2–95.2 93.2 88.6–97.8 76.1a 68.3–83.9
30–39 years 103 89.3a 83.3–95.3 93.2 88.3–98.1 82.6 75.3–89.9
40–49 years 104 90.4a 84.7–96.1 88.5a 82.4–94.6 88.5 82.4–94.6
50–59 years 90 87.8a 81.0–94.6 86.7a 79.7–93.7 85.6 78.3–92.9
60–69 years 107 86.0a 79.4–92.6 86.0a 79.4–92.6 86.9 80.5–93.3
‡ 70 years 95 87.4a 80.7–94.1 88.4a 82.0–94.8 85.3 78.2–92.4
Total 1064 91.1 89.4–92.8 92.1 90.5–93.7 83.1 80.8–85.4
aSigniﬁcant differences between this age group and the age group with the highest
prevalence (5–9 years).
Table 2. Age-speciﬁc geometric mean titre (GMT) of
antibodies (95% conﬁdence interval (CI)) for poliovirus
types 1, 2 and 3 in 1064 individuals living in northern
Greece, 2001–2002
Age group
No.
tested
Poliovirus type
1 GMT
Poliovirus type
2 GMT
Poliovirus type
3 GMT
Value 95% CI Value 95% CI Value 95% CI
3–11 months 66 7.0 6.4–7.6 7.1 6.4–7.6 6.5 5.8–7.1
1–4 years 91 6.6 6.2–7.0 6.7 6.3–7.0 5.7 5.3–6.1
5–9 years 107 6.2 5.8–6.5 6.2 5.8–6.5 5.2a 4.8–5.6
10–14 years 104 5.7 5.3–6.1 5.6a 5.3–6.0 4.9a 4.5–5.4
15–19 years 80 5.2a 4.8–5.6 5.1a 4.7–5.6 4.5a 4.2–4.9
20–29 years 117 5.3a 5.0–5.6 5.2a 4.8–5.5 4.8a 4.4–5.2
30–39 years 103 5.1a 4.8–5.4 5.3a 5.0–5.6 4.9a 4.6–5.3
40–49 years 104 5.3a 5.0–5.6 5.4a 5.0–5.7 5.1a 4.8–5.4
50–59 years 90 5.1a 4.7–5.4 5.2a 4.8–5.6 4.9a 4.5–5.2
60–69 years 107 5.1a 4.7–5.4 5.1a 4.7–5.4 5.2a 4.9–5.6
‡ 70 years 95 5.3a 4.9–5.7 5.4a 5.0–5.7 5.0a 4.7–5.4
Total 1064 5.6 5.5–5.7 5.6 5.5–5.7 5.1 5.0–5.2
aSigniﬁcant difference between this age group and the groups with the highest
GMT (3 months to 4 years).
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ABSTRACT
Amikacin-resistant Escherichia coli strains are iso-
lated rarely from clinical samples. In the present
study, investigation of an amikacin-resistant clin-
ical isolate of E. coli demonstrated the presence of
two class 1 integrons carrying the aacA4 gene plus
the aacA7 gene, and the dfrA17 gene plus the
aadA5 gene, respectively. Resistance to amikacin
in this E. coli isolate was related to the presence of
both aacA4 and aacA7.
Keywords aac genes, amikacin, Escherichia coli, integ-
rons, resistance
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During recent years, a dramatic increase has been
observed in the number of multiresistant micro-
organisms. In Escherichia coli, high levels of resist-
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